Leyden James J, Nighland Marge, Rossi Ana Beatris, Ramaswamy Ratna
Department of Dermatology, University of Pennsylvania, Philadelphia, USA.
J Drugs Dermatol. 2010 Aug;9(8):998-1003.
This single-center, investigator-blinded, randomized, split-face, phase 4 study compared the irritation potential of tretinoin gel microsphere (TGM) 0.04% in a pump dispenser with adapalene 0.1% plus benzoyl peroxide 2.5% gel (ADA-BPO 0.1%/2.5%) in a panel of 170 subjects. Participants were treated with TGM 0.04% pump on a randomly assigned side of the face and ADA-BPO 0.1%/2.5% gel on the other side of the face daily for three consecutive weeks. Expert grader assessments of erythema and dryness and subject self-assessments of burning/stinging and itching were conducted daily, except on weekends. TGM 0.04% pump was associated with better facial tolerance as demonstrated by significantly less cumulative erythema (P < 0.0001), dryness (P < 0.0001), burning/stinging (P < 0.0001) and itching (P < 0.0001) compared with ADA-BPO 0.1%/2.5% gel. While both agents were well tolerated by most patients, TGM 0.04% pump demonstrated significantly better tolerance than ADA-BPO 0.1%/2.5% gel in both neurosensory parameters and signs of contact irritation.
这项单中心、研究者设盲、随机、半脸对照的4期研究,在170名受试者中比较了0.04%维甲酸凝胶微球(TGM)泵剂型与0.1%阿达帕林加2.5%过氧化苯甲酰凝胶(ADA-BPO 0.1%/2.5%)的刺激可能性。参与者在随机分配的一侧面部使用0.04% TGM泵剂型,另一侧面部每天使用ADA-BPO 0.1%/2.5%凝胶,连续使用三周。除周末外,每天由专家评分员评估红斑和干燥情况,并由受试者自我评估灼烧/刺痛和瘙痒情况。与ADA-BPO 0.1%/2.5%凝胶相比,0.04% TGM泵剂型的面部耐受性更好,表现为累积红斑(P < 0.0001)、干燥(P < 0.0001)、灼烧/刺痛(P < 0.0001)和瘙痒(P < 0.0001)显著减少。虽然两种药物在大多数患者中耐受性良好,但在神经感觉参数和接触性刺激迹象方面,0.04% TGM泵剂型的耐受性明显优于ADA-BPO 0.1%/2.5%凝胶。